Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nothing Is Undruggable: Novartis' Bradner On CAR-T, CRISPR & DNA Libraries

Executive Summary

The head of Novartis' early drug discovery engine NIBR has a zealous sense of mission and says he is being given the resources and talent to accomplish it. "Nothing is undruggable," is his premise.

You may also be interested in...



BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases

BIO is investigating why psychiatric, cardiovascular and some other disease areas draw less deal-making and investment interest. Trillium CEO Niclas Stiernholm talks about the relative lack of VC funding for Canadian biotechs. And Novartis' Jay Bradner shares progress from the company's entrepreneurial NIBR Scholars experiment.

BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases

BIO is investigating why psychiatric, cardiovascular and some other disease areas draw less deal-making and investment interest. Trillium CEO Niclas Stiernholm talks about the relative lack of VC funding for Canadian biotechs. And Novartis' Jay Bradner shares progress from the company's entrepreneurial NIBR Scholars experiment.

Novartis Drug Discovery Centralization Brings R&D Relocations, Job Cuts

Novartis' efforts to rationalize and centralize its drug discovery programs will see the Novartis Institute for Tropical Diseases moved from Singapore to California and the closure of biologics units in Shanghai and in the Swiss town of Schlieren.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel